OSE Immunotherapeutics
Clinical-stage biotech developing immune therapies for oncology and inflammation.
OSE | PA
Overview
Corporate Details
- ISIN(s):
- FR0012127173 (+2 more)
- LEI:
- 969500HIUWVGY6NZSM05
- Country:
- France
- Address:
- 22 BOULEVARD BENONI GOULLIN, 44200 NANTES
- Sector:
- Manufacturing
Description
OSE Immunotherapeutics is a clinical-stage biotechnology company focused on developing and partnering first-in-class therapies that control the immune system. The company's pipeline is concentrated in two key areas: immuno-oncology (IO) and immuno-inflammation (I&I). In immuno-oncology, its research aims to help the immune system recognize and target tumors. In immuno-inflammation, it develops treatments for autoimmune diseases and chronic inflammation by regulating immune responses. OSE Immunotherapeutics utilizes proprietary drug discovery platforms to generate novel product candidates, including monoclonal antibodies and RNA therapeutics, and collaborates with pharmaceutical partners to advance its assets through clinical development.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-05-30 18:15 |
OSE Immunotherapeutics Provides Business and Corporate Update
|
English | 354.5 KB | ||
| 2024-05-29 18:00 |
Mise à disposition des documents préparatoires à l’Assemblée générale mixte du…
|
French | 232.1 KB | ||
| 2024-05-22 07:30 |
OSE Immunotherapeutics et Boehringer Ingelheim étendent leur collaboration pour…
|
French | 276.1 KB | ||
| 2024-05-22 07:30 |
OSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop…
|
English | 287.4 KB | ||
| 2024-05-13 18:00 |
Informations relatives au nombre total de droits de vote et d’actions composan…
|
French | 222.8 KB | ||
| 2024-05-02 18:00 |
Mise à disposition du Document d’Enregistrement Universel incluant le Rapport …
|
French | 225.0 KB | ||
| 2024-04-30 20:09 |
DOCUMENT D'ENREGISTREMENT UNIVERSEL OSE IMMUNO 2023
|
French | 15.7 MB | ||
| 2024-04-16 18:00 |
OSE Immunotherapeutics annonce l’entrée en vigueur de la licence mondiale pour …
|
French | 275.1 KB | ||
| 2024-04-16 18:00 |
OSE Immunotherapeutics’ Global License to Develop a Novel Monoclonal Antibody f…
|
English | 213.0 KB | ||
| 2024-04-10 18:00 |
OSE Immunotherapeutics reçoit un financement public de 8,4 M€ pour soutenir l’e…
|
French | 383.3 KB | ||
| 2024-04-10 18:00 |
OSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Regist…
|
English | 411.2 KB | ||
| 2024-04-03 18:00 |
Informations relatives au nombre total de droits de vote et d’actions composan…
|
French | 222.6 KB | ||
| 2024-04-02 07:30 |
OSE Immunotherapeutics annonce une publication sur CLEC-1, point de contrôle im…
|
French | 306.0 KB | ||
| 2024-04-02 07:30 |
OSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Imm…
|
English | 285.9 KB | ||
| 2024-03-27 18:00 |
OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Bu…
|
English | 433.5 KB |
Automate Your Workflow. Get a real-time feed of all OSE Immunotherapeutics filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for OSE Immunotherapeutics
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for OSE Immunotherapeutics via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-06-19 | N/A | Other | Other | 10,000 | 35,700.00 EUR |
| 2024-06-17 | N/A | Other | Other | 10,000 | 35,800.00 EUR |
| 2024-06-17 | N/A | Other | Other | 10,000 | 35,700.00 EUR |
| 2024-06-13 | N/A | Other | Sell | 6,369 | 45,879.09 EUR |
| 2024-06-03 | N/A | Other | Sell | 40,000 | 314,512.00 EUR |
Peer Companies
